77 Recruiting Urothelial Carcinoma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Urothelial Carcinoma
Related Conditions
Top Recruiting Urothelial Carcinoma Studies
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
📍 Highlands Oncology Group - Springdale /ID# 270290 — Springdale, Arkansas
View Study & Checklist ➔Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
📍 Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania
View Study & Checklist ➔A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
📍 Indiana University — Bloomington, Indiana
View Study & Checklist ➔Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma
📍 Stephenson Cancer Center — Oklahoma City, Oklahoma
View Study & Checklist ➔Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
📍 Exelixis Clinical Site #53 — Gilbert, Arizona
View Study & Checklist ➔Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
📍 USC Norris Hospital and Clinics — Los Angeles, California
View Study & Checklist ➔A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
📍 University of Chicago — Chicago, Illinois
View Study & Checklist ➔Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
📍 UCLA Institute of Urologic Oncology — Los Angeles, California
View Study & Checklist ➔Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder
📍 Fox Chase Cancer Center — Philadelphia, Pennsylvania
View Study & Checklist ➔A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
📍 Rocky Mountain Cancer Centers — Aurora, Colorado
View Study & Checklist ➔Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
📍 BCG Oncology — Phoenix, Arizona
View Study & Checklist ➔Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
📍 Banner Gateway Medical Center — Gilbert, Arizona
View Study & Checklist ➔Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma
📍 University of Florida Health Science Center — Gainesville, Florida
View Study & Checklist ➔A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
📍 Banner Gateway Medical Center — Gilbert, Arizona
View Study & Checklist ➔A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
📍 University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045) — Orange, California
View Study & Checklist ➔Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
📍 Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California
View Study & Checklist ➔Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer
📍 University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
View Study & Checklist ➔Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)
📍 Vancouver Prostate Centre — Vancouver,
View Study & Checklist ➔Circulating Tumor DNA Response In Urothelial Cancer
📍 OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma
View Study & Checklist ➔uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
📍 Providence St. Johns Health Center — Santa Monica, California
View Study & Checklist ➔Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
📍 University of Nebraska Medical Center — Omaha, Nebraska
View Study & Checklist ➔Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
📍 Tri Valley Urology Medical Group — Murrieta, California
View Study & Checklist ➔Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
📍 Fox Chase Cancer Center — Philadelphia, Pennsylvania
View Study & Checklist ➔Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
📍 Jesse Brown Department Of Veterans Affairs Medical Center — Chicago, Illinois
View Study & Checklist ➔Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
📍 Baptist Alliance MCI — Miami, Florida
View Study & Checklist ➔